David P. Hochman is the CEO of Orchestra BioMed Holdings, Inc., a company focused on healthcare innovation. He joined the company in January 2023 when it underwent a major business combination. Hochman leads with a hands-on approach, making key decisions...

David P. Hochman is the CEO of Orchestra BioMed Holdings, Inc., a company focused on healthcare innovation. He joined the company in January 2023 when it underwent a major business combination. Hochman leads with a hands-on approach, making key decisions for the company’s future in medical technology. In 2023, his total pay was $942,000, which included a bonus tied to corporate performance. This shows he's not just in it for the salary, but also motivated by results. His personal investments in company shares have seen significant highs and lows, with transactions in 2023 peaking at $6 million in December. These fluctuations reflect his active management style and belief in the company's mission. Hochman previously worked to build a strong team of experts to advance their clinical programs, pushing for regulatory approvals. His leadership during this transition is crucial, as the company aims to impact patients and healthcare on a larger scale. He is currently serving a term that extends through 2026, which aligns with the company's growth strategy and goals.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

O

David P. Hochman

Founder and CEO of Orchestra BioMed Holdings, Inc.

Education

B.A. with honors from the University of Michigan

Field of Expertise

Business & Management - Entrepreneurship

Sector of Economy

Healthcare

Born

May 12, 1975 - 49 years ago

CEO of Orchestra BioMed Holdings, Inc. for

2 years 2 months (Jan 2023 - Present)

Previous Experience

Co-founder and CEO of Legacy Orchestra and its predecessors

Rivals

Competitors/colleagues of David P. Hochman

Holdings

See how much did David P. Hochman make over time.

David P. Hochman's investment activities in Orchestra BioMed reflect a dynamic approach to his holdings. In 2023, his transactions showed considerable activity, peaking at $6 million of insider trading in December. This indicates a belief in the company's potential, especially...

David P. Hochman's investment activities in Orchestra BioMed reflect a dynamic approach to his holdings. In 2023, his transactions showed considerable activity, peaking at $6 million of insider trading in December. This indicates a belief in the company's potential, especially as it transitioned into a more public entity. Fluctuations in his holdings suggest a strategic approach, capitalizing on various market conditions. At times, he had significant portions of his wealth invested in Orchestra. His financial moves from January to August 2023 illustrate a keen awareness of the market, indicating he actively manages his holdings and believes in the long-term vision of Orchestra. Such engagement not only reflects his financial commitment but also aligns his interests with those of the company and its stakeholders.

Insider Trading

See recent insider trades of David P. Hochman.

OBIO

$35.68K

OBIO at $4.76/share

Sep 24, 2024

Purchase

OBIO

$12.28K

OBIO at $4.91/share

Sep 24, 2024

Purchase

OBIO

$14.60K

OBIO at $5.84/share

Aug 14, 2024

Purchase

OBIO

$6.95K

OBIO at $6.95/share

Jun 25, 2024

Purchase

OBIO

$15.45K

OBIO at $5.15/share

May 16, 2024

Received

OBIO

$15.45K

OBIO at $5.15/share

May 16, 2024

Purchase

OBIO

$9.50K

OBIO at $4.75/share

May 16, 2024

Received

OBIO

$9.50K

OBIO at $4.75/share

May 16, 2024

Purchase

OBIO

100,000 shares

OBIO

May 8, 2024

Received

OBIO

100,000 shares

OBIO

May 8, 2024

Received

Compensation History

See how much did David P. Hochman make over time.

In 2023, David P. Hochman's total compensation was $942,000, which included a base salary of $595,000 and a bonus of $347,000 tied to achieving corporate goals. The bonus structure incentivizes performance, showing that he is rewarded when the company does well. However, there were no stock grants or options reported for him, indicating a focus on salary and bonuses rather than stock-based compensation currently. This compensation approach aligns his interests with the company's success without relying too heavily on stock market performance. Hochman's pay reflects a compensation philosophy aimed at attracting and retaining top talent while aligning executive performance with shareholder interests. His package is designed to motivate him while the company navigates growth and innovation in the healthcare sector.

Year

2023

Total Compensation

$942.00K

Salary

$595.00K

Board Justification

The compensation program is designed to attract, retain, and reward key employees, aligning their interests with those of stockholders through performance-based incentives.

Bonus

$347.00K

Board Justification

The annual non-equity incentive plan bonus for 2023 was based on the achievement of corporate goals and objectives, with a target bonus of 80% of base salary, resulting in a bonus of 75% of the target due to performance.

Other

$0.00

Board Justification

No other compensation was reported for 2023.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock was reported as vested in 2023 for David P. Hochman.

Performance Metrics

Performance metrics included advancing clinical programs and achieving regulatory approvals.